Press release | 25th May 2011

PharmaLegacy Laboratories Achieves a Tenfold Improvement in Validated Reporting Time

IDBS E-WorkBook Suite Delivers Significant Time and Cost Benefits to CROs and Clients

Guildford, UK, and Burlington, Mass., May 25, 2011 – IDBS, a global provider of innovative data management, analytics and modeling solutions, announced that PharmaLegacy Laboratories, a leading Shanghai-based CRO, has reported a dramatic improvement in the production of validated regulatory customer reports from 10 days to a single day using IDBS E-WorkBook Suite.

PharmaLegacy Laboratories offers specialty preclinical services for a worldwide clientele. They implemented E-WorkBook for Biology (BioBook) to provide their clients with quality assurance on their processes and research methods and to offer preclinical study data at a faster pace with higher efficiency. BioBook is part of the E-WorkBook Suite, the world’s fastest growing R&D data management solution, and is the dominant biology-focused workflow application in pharmaceuticals and life sciences. Deploying BioBook instantly provided PharmaLegacy with the same quality of data management and collaboration control capability as many of its largest customers, which are international pharmaceutical and biotech companies.

“We are very pleased to have such fantastic return on investment, particularly through reducing our time from data generation to validated report,” said Mei-Shu Shih, CSO of PharmaLegacy. “The solution has enabled us to spend more time on projects and capture our results with unparalleled security, more easily communicate across departments and accelerate research into the development and effectiveness of new therapies. These advantages only accrue through BioBook’s full electronic capture, analysis and reporting capabilities, and as a result our organization can deliver faster turnaround times with cost savings to our clients.”

PharmaLegacy can assure existing and prospective customers that their data is protected to the highest international standards and can demonstrate that faster discoveries can be made through efficient and effective research data management methods. BioBook is FDA 21 CFR Part 11 compliant and was the first Electronic Laboratory Notebook (ELN) to be certified compliant with SAFE-BioPharma. This enables PharmaLegacy to collaborate on research across its global sites and with customers, while ensuring that any new discoveries are protected with industry-leading levels of security.

“We are delighted that BioBook has made such an impact to PharmaLegacy’s reporting times. In this competitive marketplace, the need for CROs to increase the number of successful drug candidates is paramount,” said Neil Kipling, founder and CEO of IDBS. “Results since deployment at PharmaLegacy demonstrate the benefit and necessity of choosing effective data management solutions for preclinical research. BioBook provides an excellent solution to reduce costs, deliver maximum return on investment and accelerate the pace of drug development.”

About PharmaLegacy

PharmaLegacy Laboratories is an advanced preclinical Contract Research Organization (CRO) with established state-of-the-art facilities in the Zhangjiang High-Tech Park, Shanghai, PRC.

The company has extensive experience in providing specialty pharmacology services to multinational pharmaceutical and biotechnology companies across many therapeutic areas including: Bone Metabolism, Immune Diseases, Inflammation, Orthopedics and Oncology. PharmaLegacy also offers a full range of preclinical pharmacology services on new drug/medical device candidates from R&D to IND/IDE, incorporating rigorous science in a cost-effective manner. For more information please visit

About IDBS

IDBS is a global provider of innovative enterprise data management, analytics and modeling solutions. The company’s uniquely sophisticated platform technologies are used by more than 200 pharmaceutical companies, major healthcare providers, global leaders in academic study, and high tech companies to increase efficiency, reduce costs and improve the productivity of industrial R&D and clinical research. IDBS is clearly differentiated by its unique combination of award-winning enterprise technologies and domain knowledge in R&D.

IDBS’ solutions help scientists, hospitals and R&D businesses produce the world’s newest therapeutics, diagnostics and personalized treatments, faster, cleaner engines and fuels, breakthroughs in productive agriculture, healthy, safer food products, and high tech materials and consumer products.

Founded in 1989 and privately held, IDBS is headquartered in Guildford, UK with a direct sales and support presence worldwide. IDBS is a Profit Track 100 company and the recipient of multiple awards including the Frost and Sullivan ‘Enabling Technology’ Award in R&D data management for 2010 and Queen’s Award for International Trade 2011. Further information can be found at, or follow us on Twitter @IDBSsoftware.

More news